GBA1 and Parkinson disease: In this study, we found that treatment with the lipid substrate-reducing compound Genz-123346, which inhibits glycosphingolipid biosynthesis, decreases mTORC1 activity, and restores TFEB expression in the GBA1 mutant PD neurons.